Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Secukinumab - Novartis

Drug Profile

Secukinumab - Novartis

Alternative Names: AIN-457; Anti-interleukin 17A monoclonal antibody; Cosentyx; KB-03303A; NVP-AIN-457; Scapho

Latest Information Update: 10 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alcon; Novartis
  • Developer Beth Israel Deaconess Medical Center; GWT-TUD GmbH; Icahn School of Medicine at Mount Sinai; Novartis
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Preregistration Non-radiographic axial spondyloarthritis
  • Phase III Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Rheumatoid arthritis
  • Phase II Alopecia areata; Atopic dermatitis; Giant cell arteritis; Necrobiosis lipoidica; Tendon injuries
  • Discontinued Asthma; Crohn's disease; Dry eyes; Multiple sclerosis; Polymyalgia rheumatica; Type 1 diabetes mellitus; Uveitis

Most Recent Events

  • 07 Nov 2019 Novartis plans a phase III trial for Ankylosing spondylitis or Non-radiographic axial spondyloarthritis (Treatment-experienced) in USA and other unknown countries in December 2019 (IV)(NCT04156620)
  • 01 Nov 2019 Efficacy and safety data from a phase III EXCEED 1 trial Psoriatic arthritis in released by Novartis
  • 23 Oct 2019 The European Commission approves label update for the up-titration of secukinumab to 300 mg for Ankylosing spondylitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top